That firm, Ganymed Pharmaceuticals, was sold to Astellas Pharmaceuticals in 2016 for $460 million (plus an additional $940 million if certain milestones were met). About GANYMED GANYMED Pharmaceuticals AG is a leading biopharmaceutical company offering smart antibody therapeutics for ideal targets in solid cancers. Get the latest Galmed Pharmaceuticals Ltd. GLMD detailed stock quotes, stock … Per Forbes, Ganymed received backing from … This unmatched. Türeci: Stock option owner, ex-shareholder, cofounder & CEO of Ganymed Pharmaceuticals AG, has received consultancy fees from Astellas, and has several patents issued to this work that have been acquired by Astellas. The chimeric IgG1 antibody IMAB362 which is directed against CLDN18.2 has been developed by Ganymed Pharmaceuticals AG. Ganymed Pharmaceuticals acquired by Astellas Pharma, Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of current team members an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals AG (“Ganymed”), a biopharmaceutical company located in Mainz, Germany, and Ganymed has become a wholly owned subsidiary of Astellas as of CET December 20, 2016. Selexis SA Signs Commercial License Agreement With GANYMED Pharmaceuticals AG. Founder of BioNTech SE, Ganymed Pharmaceuticals AG, Ci3 Management UG and TRON - Translationale Onkologie an der Universitätsmedizin der, Ugur Sahin currently is Chief Executive Officer for BioNTech SE and Managing Director at reBOOST Management GmbH (a subsidiary of BioNTech SE) and Managing Director at Medine GmbH. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. 09 Sep 2017. Das biopharmazeutische Unternehmen, 2001 als Spin-off der Universitäten Mainz und Zürich gegründet, entwickelt Antikörper zur gezielten Krebstherapie (Ideal Monoclonal Antibodies - IMABs). Information about your device and Internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. GANYMED Pharmaceuticals AG | 456 followers on LinkedIn. 10 Erfahrungsberichte von Mitarbeitern liefern dir die Antwort. GANYMED Pharmaceuticals AG is a biotechnology company based out of 12Freiligrathstraße, Mainz, Rhineland-Palatinate, Germany. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. In fünf Finanzierungsrunden zwischen 2002 und 2013 hatten die Kapitalgeber rund 160 Mio. ATS Acquires Majority Shareholding in GANYMED Pharmaceuticals AG. Diese sind selektiv auf Proteine auf der Krebszelloberfläche. By clicking "Accept all" you agree that Verizon Media and our partners will store and/or access information on your device through the use of cookies and similar technologies and process your personal data, to display personalised ads and content, for ad and content measurement, audience insights and product development. Scientific advisor of Ganymed, of BioNTech and of TRON. Die 2001 gegründete Ganymed Pharmaceuticals entwickelt immuntherapeutische Krebsmedikamente. : +49(0)6131-1440-109 e-mail: [email protected] Media Contact Frank Butschbacher, CIR Investor Relations & Communications Ganymed Pharmaceuticals is actively using 2 technologies for its website, according to BuiltWith. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects. Ganymed Pharmaceuticals General Information Description. Resources from the same session. Forschungsschwerpunkte: GANYMED Pharmaceuticals AG ist ein führendes biopharmazeutisches Unternehmen, das hoch tumorspezifische Antikörperwirkstoffe gegen neue Zielstrukturen zur gezielten Behandlung solider Tumore entwickelt.Das Unternehmen verfügt über eine der leistungsstärksten integrierten Komplettlösungen im Bereich der Antikörpertherapeutika, von der Identifizierung … Executive board member of CI3-Cluster. tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. WhatsApp acquired by Facebook). Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). View Galmed Pharmaceuticals Ltd. GLMD investment & stock information. Capital Stock: EUR 1,416,308 (as of end of May 2016) ... About Ganymed. IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. Here are 3 reasons why the stock market can survive rising bond yields in 2021. 8/21/2008. To enable Verizon Media and our partners to process your personal data select 'I agree', or select 'Manage settings' for more information and to manage your choices. These include MarkMonitor DNS and 040 Hosting. GANYMED Pharmaceuticals AG gab den Verkauf einer Aktienmehrheit an die ATS bekannt. IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. 4/18/2007 MAINZ, Germany, June 5, 2016 /PRNewswire/ -- Ganymed Pharmaceuticals AG, a biopharmaceutical company developing highly targeted immunotherapies against cancer, announced outstanding data from its randomized Phase II clinical study of IMAB362 in first-line treatment of gastric cancer at the ASCO 2016 Annual Meeting. C. Huber: Stock owner of Ganymed and of BioNTech shares. IMAB362 recognizes the first extracellular domain (ECD1) of CLDN18.2 with high affinity and specificity. Then, in 2001, they founded Ganymed Pharmaceuticals, which focused on the role of antibodies in treating cancer. Die Gesellschafterversammlung vom 03.03.2017 hat die formwechselnde Umwandlung in die gleichzeitig errichtete Ganymed Pharmaceuticals GmbH mit Sitz in Mainz (Amtsgericht Mainz, HRB … Corporate Name: Ganymed Pharmaceuticals AG (2) Location: Mainz, Germany (3) Representative: Özlem Türeci, CEO (4) Founded year: 2001 (5) Capital Stock: EUR 1,416,308 (as of end of May 2016) (6) Number of employees: 85 (7) Relationship with Astellas: There is no relationship between Astellas and Ganymed required to be disclosed 7/11/2007. Active, Closed, Last funding round type (e.g. Capital Stock: EUR 1,416,308 (as of ... About Ganymed Ganymed Pharmaceuticals AG is a biopharmaceutical company developing a new class of immunotherapeutic cancer … Member of Ganymed\'s and of BioNTech´s supervisory board. In 2016, Ganymed was sold to Japanese pharmaceutical company Astellas Pharma for $1.4 billion. Ganymed Pharmaceuticals Germany Acquired Ganymed Pharmaceuticals AG is a leading biopharmaceutical company offering smart antibody therapies for ideal targets in solid cancers. GANYMED Pharmaceuticals AG Closes EUR 65 M Financing Round. The company's discovery engine is one of the industry’s most powerful integrated approaches to building an antibody cancer pipeline. Ganymed Pharmaceuticals uses 5 technology products and services including HTML5, jQuery, and Google Fonts, according to G2 Stack. Ganymed Pharmaceuticals AG is a German biotech company focusing on the development of a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs) for the treatment of solid cancers. Ganymed Pharmaceuticals is a biopharmaceutical developing therapeutic drugs designed to kill tumor cells without harming healthy tissues. The company is building a pipeline of antibody therapeutics targeting solid cancers with medical need and large-market potential. Erfahre aus erster Hand, ob GANYMED Pharmaceuticals als Arbeitgeber zu dir passt. Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). This study was designed by Ganymed Pharmaceuticals GmbH, in collaboration with the investigators, and was conducted in accordance with the Declaration of Helsinki ethical principles, Good Clinical Practices, principles of informed consent, and requirements of public registration of clinical trials (ClinicalTrials.gov Identifier, NCT01197885). Dadurch zerstören sie die Tumorzellen, nicht aber das gesunde Gewebe. Speaker: Roche, Celgene, Lilly, Nordic Pharma. Company profile page for Ganymed Pharmaceuticals AG including stock price, company news, press releases, executives, board members, and contact information Tokyo and Mainz, October 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, 'Astellas') and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, 'Ganymed'), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed's shareholders have entered into an … In October 2016 Astellas announced it would acquire Ganymed Pharmaceuticals for $1.4 billion In April 2017, the company announced it would acquire Belgium-based drug discovery firm Ogeda for up to a total €800 million, strengthening its late-stage pipeline with Ogeda's drug candidate, fezolinetant. You can change your choices at any time by visiting Your privacy controls. IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. Developer of antibody therapeutics for the treatment of solid cancers. Here's Why Ionis Pharmaceuticals Stock Got Slammed Today The biotech's partner is stopping a late-stage clinical trial for a Huntington's disease treatment. Ganymed, Sahin’s first company backed by the Struengmanns, was acquired by Japanese pharmaceutical giant Astellas in 2016 for $460 million — plus … 11/18/2008. EUR in Ganymed investiert. Die japanische Astella Pharma Inc. übernimmt die in Mainz ansässige Ganymed Pharmaceuticel AG. U. Advisory role: Merck, Roche, Celgene, Lilly, Nordic Pharma. Visit site. Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). HRB 7897: Ganymed Pharmaceuticals AG, Mainz, An der Goldgrube 12, 55131 Mainz. Ganymed's IMAB362 Extends Survival in Gastric Cancer. Find the latest Galmed Pharmaceuticals Ltd. (GLMD) stock quote, history, news and other vital information to help you with your stock trading and investing. Overview of Acquired Company (1) Corporate Name: Ganymed Pharmaceuticals AG (2) Location: Mainz, Germany (3) Representative: Özlem Türeci, CEO (4) Founded year: 2001 (5) Capital Stock: EUR 1,416,308 (as of end of May 2016) (6) Number of employees: 85 (7) Ganymed Pharmaceuticals AG An der Goldgrube 12 55131 Mainz Germany Tel. Legal Advisor to Ganymed`shareholders: Freshfields Bruckhaus Deringer, honert + partner. GANYMED Pharmaceuticals AG Raises Euro 33.7 Million in Series C Financing Round. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g.